---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-004946"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:50:13.261012+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics Q2 net loss $11.3M; BTC top-line data pushed to H2 2024

## Summary
- Net loss of $11.3M ($0.09/share) in Q2 2023 vs $8.5M loss ($0.08/share) in Q2 2022.
- Cash and marketable securities $169M as of June 30, 2023; cash runway into 2026.
- R&D expense $10.2M in Q2 2023, up 74% YoY driven by CTX-009 clinical and manufacturing costs.
- CTX-009 Phase 2 CRC initial data still expected H2 2023; BTC top-line data delayed to H2 2024 due to slower enrollment.
- CTX-8371 (PD-1 x PD-L1) IND submission targeted Q3 2023 with Phase 1 start in Q4 2023.

## SEC filing metadata
- accession: 0001171843-23-004946
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184323004946/0001171843-23-004946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184323004946/f8k_080223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-004946
- JSON: https://secwatch.observer/filing/0001171843-23-004946.json
- Plain text: https://secwatch.observer/filing/0001171843-23-004946.txt

## Key facts
- Earnings Releases
  Compass Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the second quarter ended June 30, 2023 was $11.3 million or $0.09 per common share, EPS $0.09 per common share.
  - Period: the second quarter ended June 30, 2023
  - Net income: Net loss for the second quarter ended June 30, 2023 was $11.3 million or $0.09 per common share
  - EPS: $0.09 per common share
  - Result: reported results
  source text: On August 3, 2023, Compass Therapeutics, Inc. issued a press release announcing financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184323004946/0001171843-23-004946-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.